Welcome to our dedicated page for UNITED GUARDIAN SEC filings (Ticker: UG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UNITED GUARDIAN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UNITED GUARDIAN's regulatory disclosures and financial reporting.
United-Guardian (UG) filed its Q3 2025 10-Q reporting lower sales and earnings. Net sales were $2,264,261, down from $3,060,113 a year ago, with nine‑month sales at $7,583,613 versus $9,705,262. Net income was $268,441 in the quarter (vs. $865,484) and $1,456,162 year‑to‑date (vs. $2,747,151). EPS was $0.06 for the quarter (vs. $0.19) and $0.32 year‑to‑date (vs. $0.60).
Mix and volume pressures weighed on margins: cost of sales rose to 58% of sales in Q3 (46% prior year) and to 50% for the nine months (47% prior year), reflecting a higher contribution from lower‑margin pharmaceuticals and lower cosmetic volumes. Cosmetic ingredient sales softened, particularly tied to China demand and tariff dynamics, while pharmaceuticals grew on both a gross and net basis.
Operating cash flow was $1,636,324 for the nine months. The company paid cash dividends of $0.35 per share in February and $0.25 per share in August. Management highlighted ongoing tariff uncertainty related to China and noted the Natrajel launch timing has shifted to 2026 due to customer timelines. Working capital remains strong with a 7.0:1 current ratio.
United-Guardian, Inc. filed a current report to note that it released an earnings-related press release. Under the item covering results of operations and financial condition, the company states that on November 6, 2025 it issued a press release, which is attached as Exhibit 99.1 and incorporated by reference. The filing itself does not include the detailed financial results, directing readers instead to the attached exhibit for full information.
United-Guardian (UG) posted softer Q2 FY25 results amid tariff-related demand weakness in Asia. Net sales fell 16% YoY to $2.84 m, pulling H1 revenue down 20% to $5.32 m. Cosmetic ingredients—heavily exposed to China through key distributor ASI—dropped 37% in the quarter, while pharmaceuticals rose 3% and medical lubricants slid 12%.
Gross margin held near 53%, but a 15% rise in operating expenses cut operating profit 38% to $0.70 m. Net income declined 34% to $0.63 m (EPS $0.14); H1 earnings were 37% lower at $1.19 m (EPS $0.26).
Operating cash flow shrank to $0.63 m from $1.97 m. Cash, equivalents and marketable securities total $8.42 m, supporting a 6.7× current ratio and debt-free balance sheet. Retained earnings eased after a $0.35/share dividend paid in Feb; another $0.25/share dividend was declared 11 Jul 25 for payment on 1 Aug 25.
Management flags heightened risk from new U.S. tariffs effective Aug-25 and possible Chinese retaliation, given ~40% of ASI resale volume is China-bound. Customer (one distributor 75%+) and supplier concentration remain structural risks. The company expects its new Natrajel sexual-wellness line to begin contributing in H2 25, offering a prospective growth lever.
United-Guardian, Inc. filed a current report describing the release of a press announcement about its results of operations and financial condition. The company stated that it issued this press release on August 8, 2025, and attached it as an exhibit for investors and the public to review.